secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-07-23T20:05:20+00:00
Accession:  0001104659-26-086254
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics receives Nasdaq extension to Jan 19, 2027 to regain $1 minimum bid price compliance
--------------------------------------------------------------------------------

- Received Nasdaq notification on July 23, 2026 granting additional 180-day compliance period until Jan 19, 2027.
- Must achieve closing bid price of $1.00 for 10 consecutive business days during extension.
- If not compliant by Jan 19, 2027, Nasdaq will issue delisting notice; company may appeal.
- Previously reported deficiency notice on Jan 23, 2026; initial 180-day period expired July 22, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926086254/0001104659-26-086254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926086254/tm2621205d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-086254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer